You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

Baxter
Medtronic
McKinsey
Moodys
Harvard Business School
Dow

Last Updated: September 30, 2020

DrugPatentWatch Database Preview

Patent: 9,181,162

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Summary for Patent: 9,181,162
Title:Compositions and methods for glucose transport inhibition
Abstract: Glucose deprivation is an attractive strategy in cancer research and treatment. Cancer cells upregulate glucose uptake and metabolism for maintaining accelerated growth and proliferation rates. Specifically blocking these processes is likely to provide new insights to the role of glucose transport and metabolism in tumorigenesis, as well as in apoptosis. As solid tumors outgrow the surrounding vasculature, they encounter microenvironments with a limited supply of nutrients leading to a glucose deprived environment in some regions of the tumor. Cancer cells living in the glucose deprived environment undergo changes to prevent glucose deprivation-induced apoptosis. Knowing how cancer cells evade apoptosis induction is also likely to yield valuable information and knowledge of how to overcome the resistance to apoptosis induction in cancer cells. Disclosed herein are novel anticancer compounds that inhibit basal glucose transport, resulting in tumor suppression and new methods for the study of glucose deprivation in animal cancer research.
Inventor(s): Chen; Xiaozhuo (Athens, OH), Bergmeier; Stephen (Athens, OH)
Assignee: Ohio University (Athens, OH)
Application Number:13/071,386
Patent Claims:see list of patent claims

Details for Patent 9,181,162

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Chiron PROLEUKIN aldesleukin VIAL 103293 001 1992-05-05   Start Trial Ohio University (Athens, OH) 2030-03-24 RX search
Amgen NEUPOGEN filgrastim VIAL 103353 001 1991-02-20   Start Trial Ohio University (Athens, OH) 2030-03-24 RX search
Amgen NEUPOGEN filgrastim VIAL 103353 002 1991-02-20   Start Trial Ohio University (Athens, OH) 2030-03-24 RX search
Amgen NEUPOGEN filgrastim SYRINGE 103353 003 1991-02-20   Start Trial Ohio University (Athens, OH) 2030-03-24 RX search
Amgen NEUPOGEN filgrastim SYRINGE 103353 004 1991-02-20   Start Trial Ohio University (Athens, OH) 2030-03-24 RX search
Sigma Tau ONCASPAR pegaspargase VIAL 103411 001 1994-02-01   Start Trial Ohio University (Athens, OH) 2030-03-24 RX search
Genentech RITUXAN rituximab SOLUTION;INTRAVENOUS 103705 001 1997-11-26   Start Trial Ohio University (Athens, OH) 2030-03-24 RX search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKinsey
Moodys
AstraZeneca
Mallinckrodt
Dow
Medtronic

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.